Literature DB >> 11930875

Randomized clinical trials in pancreatic cancer.

Alexander Stojadinovic1, Axel Hoos, Murray F Brennan, Kevin C P Conlon.   

Abstract

The authors reviewed 59 prospective, randomized, controlled trials for pancreatic carcinoma that were published between 1977 and 2000. Of the 11 surgical trials, two each studied extent of resection (standard versus pylorus-preserving pancreaticoduodenectomy) and lymphadenectomy (standard versus extended lymph node dissection), five trials compared different types of pancreaticenteric reconstruction, and one each evaluated the role of prophylactic gastrojejunostomy and chemical splanchnicectomy in the setting of advanced disease.

Entities:  

Mesh:

Year:  2002        PMID: 11930875     DOI: 10.1016/s1055-3207(03)00082-6

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  10 in total

1.  Construction of orthotopic xenograft mouse models for human pancreatic cancer.

Authors:  Lei Dai; Caide Lu; X I Yu; Long-Jun Dai; Jeff X Zhou
Journal:  Exp Ther Med       Date:  2015-07-16       Impact factor: 2.447

Review 2.  Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression.

Authors:  Seth B Krantz; Mario A Shields; Surabhi Dangi-Garimella; Hidayatullah G Munshi; David J Bentrem
Journal:  J Surg Res       Date:  2011-10-08       Impact factor: 2.192

3.  Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.

Authors:  Cristina R Ferrone; Michael W Kattan; James S Tomlinson; Sarah P Thayer; Murray F Brennan; Andrew L Warshaw
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

4.  Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas.

Authors:  Murray F Brennan; Michael W Kattan; David Klimstra; Kevin Conlon
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

5.  Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas.

Authors:  Peter Shamamian; Judith D Goldberg; Xiang Y Ye; Jonathan D Stewart; Peter J White; Charles Gilvarg
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

6.  National failure to operate on early stage pancreatic cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

7.  Laparoscopic staging and surgical treatment of pancreatic cancer.

Authors:  Thiruvengadam Muniraj; Pranav Barve
Journal:  N Am J Med Sci       Date:  2013-01

8.  Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors.

Authors:  Sanne Hindriksen; Maarten F Bijlsma
Journal:  Cancers (Basel)       Date:  2012-10-12       Impact factor: 6.639

9.  Contribution of epithelial-mesenchymal transition to pancreatic cancer progression.

Authors:  Seth B Krantz; Mario A Shields; Surabhi Dangi-Garimella; David J Bentrem; Hidayatullah G Munshi
Journal:  Cancers (Basel)       Date:  2010-12-09       Impact factor: 6.639

10.  Searching for novel multimodal treatments in oligometastatic pancreatic cancer.

Authors:  D M Filippini; E Grassi; A Palloni; R Carloni; R Casadei; C Ricci; C Serra; G Ercolani; G Brandi; M Di Marco
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.